This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Xianjun Meng
Shenyang Agricultural University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Cervical cancer is the fourth most common carcinoma in women. Cisplatin (DDP) is the first-line drug for the treatment of cervical cancer.
Although efficacious, its application is constrained by the intolerance and serious adverse effects associated with cisplatin. Here, we aimed to investigate the in vivo anti-cervical cancer effects of cyanidin-3-o-glucoside (C3G), a type of anthocyanin, and DDP, when used alone or in combination; a BALB/c nude mouse xenograft tumour model was used. The tumour was inhibited in the three treatment groups when compared with untreated controls. The inhibition of tumour was 40.49%, 50.15%, and 58.49% when treated with C3G alone [40 mg/kg body weight (bw)], DDP alone (3 mg/kg bw), or a combination of C3G and DDP, respectively. Immunohistochemistry analysis indicated that treatment with C3G, DDP, or the combination induced apoptosis in xenograft tumours. Furthermore, after treatment, Bcl-2 level was decreased, Bax and cleaved caspase-3 expression was activated, and the PI3K/AKT/mTOR signalling pathway was modulated. These results suggest that the combination of C3G and DDP may have significant synergistic anti-tumour efficacy in patients; therefore, this combination therapy has great potential for the treatment of cervical cancer.
Keywords
cervical cancer, cyanidin-3-o-glucoside, cisplatin, anti-tumor effect
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
No competing interests reported.
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 15 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 05 Apr, 2021
Review #3 received
Received 24 Mar, 2021
Review #2 received
Received 24 Mar, 2021
Review #4 received
Received 24 Mar, 2021
Review #1 received
Received 24 Mar, 2021
Reviewer #7 agreed
On 24 Mar, 2021
Reviewer #2 agreed
On 24 Mar, 2021
Reviewer #3 agreed
On 24 Mar, 2021
Reviewer #6 agreed
On 24 Mar, 2021
Reviewer #8 agreed
On 24 Mar, 2021
Reviewer #4 agreed
On 24 Mar, 2021
Reviewer #1 agreed
On 24 Mar, 2021
Reviewer #5 agreed
On 24 Mar, 2021
Reviewers invited
Invitations sent on 23 Mar, 2021
Editor assigned
On 15 Mar, 2021
Editor invited
On 08 Mar, 2021
Submission checks complete
On 08 Mar, 2021
First submitted
On 28 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Agricultural Engineering
Learn more about our company.
This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Xianjun Meng
Shenyang Agricultural University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 15 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 05 Apr, 2021
Review #3 received
Received 24 Mar, 2021
Review #2 received
Received 24 Mar, 2021
Review #4 received
Received 24 Mar, 2021
Review #1 received
Received 24 Mar, 2021
Reviewer #7 agreed
On 24 Mar, 2021
Reviewer #2 agreed
On 24 Mar, 2021
Reviewer #3 agreed
On 24 Mar, 2021
Reviewer #6 agreed
On 24 Mar, 2021
Reviewer #8 agreed
On 24 Mar, 2021
Reviewer #4 agreed
On 24 Mar, 2021
Reviewer #1 agreed
On 24 Mar, 2021
Reviewer #5 agreed
On 24 Mar, 2021
Reviewers invited
Invitations sent on 23 Mar, 2021
Editor assigned
On 15 Mar, 2021
Editor invited
On 08 Mar, 2021
Submission checks complete
On 08 Mar, 2021
First submitted
On 28 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Agricultural Engineering
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Cervical cancer is the fourth most common carcinoma in women. Cisplatin (DDP) is the first-line drug for the treatment of cervical cancer.
Although efficacious, its application is constrained by the intolerance and serious adverse effects associated with cisplatin. Here, we aimed to investigate the in vivo anti-cervical cancer effects of cyanidin-3-o-glucoside (C3G), a type of anthocyanin, and DDP, when used alone or in combination; a BALB/c nude mouse xenograft tumour model was used. The tumour was inhibited in the three treatment groups when compared with untreated controls. The inhibition of tumour was 40.49%, 50.15%, and 58.49% when treated with C3G alone [40 mg/kg body weight (bw)], DDP alone (3 mg/kg bw), or a combination of C3G and DDP, respectively. Immunohistochemistry analysis indicated that treatment with C3G, DDP, or the combination induced apoptosis in xenograft tumours. Furthermore, after treatment, Bcl-2 level was decreased, Bax and cleaved caspase-3 expression was activated, and the PI3K/AKT/mTOR signalling pathway was modulated. These results suggest that the combination of C3G and DDP may have significant synergistic anti-tumour efficacy in patients; therefore, this combination therapy has great potential for the treatment of cervical cancer.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...